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The metabolic fate of nitric oxide (NO) released from nitroaspirin, benzoic acid, 2-(acetyloxy)-3-
[(nitrooxy)methyl]phenyl ester (NCX 4016), the lead compound of a new class of NO-releasing non steroidal
anti-inflammatory drugs (NO-NSAIDs), has been studied in the rat following p.o. and i.p. administration of 100
mg/kg, by monitoring in plasma the bioactive storage forms of NO (S-nitrosothiols, RS-NO) and its oxidation
products (nitrites/nitrates, NOx) by a chemiluminescent assay. In parallel, plasma was analyzed for unchanged
drug and metabolites by reverse-phase HPLC. In orally treated rats, no unchanged drug is observed in the 0–24
h interval post-dosing, but only salicylic acid (SA), NOx and RS-NO. The time-course of SA formation parallels
that of plasma NOx (plateau after 6 h). Nitrosothiols in plasma are detectable at 1 h, peak at 4 h post-
administration, and decline thereafter. The results relative to i.p. administration show a more pronounced and
rapid NO delivery (peak of both NOx and RS-NO at 1 h and plateau between 1 and 2 h), still coincident with
the peak of SA, and the presence in plasma of NCX 4015 (a metabolite of NCX 4016 which still bears the
nitrate function). In myocardial tissue from p.o. treated rats, no drug or metabolites were ever detected, and the
NOx levels were always in the range of the controls. Conversely, following i.p. treatment, we observed a rapid
compartmentalization within the heart of the unchanged drug, which rapidly disappears in favour of its
breakdown products NCX 4015 and SA, with a concomitant rise in myocardial NOx levels up to 2 h. To check
the stability of NCX 4016 in the acidic gastric milieu and to explain the different distribution of the drug
following p.o. or i.p. administration, the gastric content of the orally-treated animals at different post-dosing0024-3205/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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M. Carini et al. / Life Sciences 74 (2004) 3291–33053292times was analysed by HPLC. The unchanged drug was detected up to 8 h post-dosing (levels slowly decreased
with time), and the only metabolite to be detected was the O-deacetylated derivative (NCX 4023), which was
present in low concentrations up to 4 h post-dosing. This indicates that NCX 4016 does not undergo
biotransformation in the upper part of gastrointestinal tract (no direct release of NO in this district) and that the
stomach acts as a reservoir for the drug.
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Introduction
Nitroaspirin, benzoic acid, 2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4016), is the lead
of a new class of anti-inflammatory/antithrombotic agents (Del Soldato et al., 1999) that has been
recently proposed by Napoli and Ignarro (2003) and Wallace et al. (2002) as a safer alternative to
aspirin for use in hypertensive patients for the primary prevention of cardiovascular diseases. The
therapeutic goal of NCX 4016 is to achieve lower gastrointestinal toxicity in comparison to aspirin
beside maintaining the anti-inflammatory action. In addition, nitroaspirin has been shown in preclinical
studies to be a promising novel agent for colon cancer prevention and treatment (Bak et al., 1998;
Rigas et al., 2003; Rigas and Williams, 2002). Both the aspirin and NO moieties of this compound
contribute to its effectiveness. The NO moiety exerts its effect through both cGMP-dependent
(inhibition of platelet aggregation, vasodilation, inhibition of leukocyte adhesion to the vascular
endothelium) and –independent mechanisms (inhibition of inflammatory cytokine synthesis, inhibition
of cell proliferation and apoptosis). For this reason the knowledge of the rate of NO release from this
novel NO-donor drug is a pivotally crucial first step in determining the time course and spectrum of its
pharmacological activity.
In previous studies we have obtained unequivocal evidence that NCX 4016, when incubated
with rat blood or when acutely administered by i.p. or oral route in the same animal is able to
release NO (Carini et al., 2001). This has been clearly demonstrated by Electron Spin Resonance
(ESR) spectroscopy determining NO in radical form as nitrosylhemoglobin HbFe(II)NO and this
analytical evidence has provided strong support that the reduced gastrolesivity of the drug in the
animal and the other pharmacological effects are due to the release of this important vasorelaxing
mediator.
As well as being an unequivocal marker of NO release, HbFe(II)NO also represents a form of delivery
of NO in the blood. In particular, according to the recent theory of modulation of NO bioavailability by
erythrocytes (Pawloski et al., 2001; Gow et al., 1999), NO enters the RBC and preferentially binds to the
free heme to form HbFe(II)NO. This last then transfers NO to h-93-Cys to form S-nitroso-Hb. Bioactive
NO is then exported out of RBCs through the anion exchange protein, band 3 (or AE1), to redox-active
thiols which are abundant in plasma and can incorporate NO and transport it in the circulation in the
form of bioactive S-nitrosothiols (RS-NO).
Based on this recent proposed mechanism, as well as being a paracrin mediator, NO can also be
considered an endocrine vasoregulator (at least at pharmacological doses) that is able to act distal to
the site of its formation through the presence of species in blood that are capable of delivering NO,
such as S-nitrosothiols, iron-nitrosyl complexes and nitrites (Gladwin et al., 2003). Since the growing
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(Miller et al., 2003; Alencar et al., 2003; Rassaf et al., 2002), the first aim of this work was to gain a
deeper insight into the metabolic fate of NO released from NCX 4016 following p.o. and i.p.
administration, by monitoring the plasma levels of the bioactive storage forms of S-nitrosothiols and of
nitrites/nitrates (NOx) and to correlate their kinetics of formation with those of plasma levels of the
drug and its metabolites. NCX 4016 requires in fact enzymatic denitration to liberate NO (Napoli and
Ignarro, 2003) and, as previously demonstrated in in vitro studies in rat liver, the molecule undergoes
rapid metabolization of the ester linkage to salicylic acid (SA) and benzenemethanol,3-hydroxy-a-
nitrate (NCX 4015), the spacer still bearing the nitrate ester, the function more resistant to reductive
hydrolysis (Carini et al., 2002).
In the second part of this study we have analysed (HPLC) along the entire post-dosing time, the
gastric content of rats p.o. treated with 100 mg/kg. This was done in order to exclude production of NO/
nitrosating species locally in the stomach with potential risk of toxicity, and to determine the kinetics of
release from the stomach of NCX 4016 and metabolites.Materials and methods
Chemicals
HPLC-grade and analytical-grade organic solvents were purchased from Merck (Bracco, Milan,
Italy). HPLC-grade water was prepared with a Milli-Q water purification system. Benzoic acid, 2-
(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester (NO-ASA; NCX 4016) and the NO-ASA metabolites:
benzoic acid, 2-(hydroxy)-3-[(nitrooxy)methyl]phenyl ester (NCX 4023), benzoic acid, 2-(acetyloxy)-3-
(hydroxymethyl)phenyl ester (NCX 4017), benzoic acid, 2-(hydroxy)-3-(hydroxymethyl)phenyl ester
(NCX 4019) and benzenemethanol,3-hydroxy-a-nitrate (NCX 4015) were kindly provided by NICOX
S.A. (Sophia Antipolis, France); benzenemethanol, 3-hydroxy (HBA), benzoic acid, 3-hydroxy
(HBAC), acetylsalicylic acid (ASA), salicylic acid (SA), ortho-phosphoric acid (85% w/v), sodium
fluoride and N-ethylmaleimide (NEM) were purchased from Fluka Chimica (Milan, Italy). Polyethylene
glycol (PEG 400; average molecular weight, 400), potassium iodide, vanadium (III) chloride,
sulfanilamide (p-aminobenzenesulfonamide), copper (II) sulphate, ethylene-diaminetetraacetic acid,
perchloric acid, glacial acetic acid and h-glucuronidase (4.5 U/ml)/arylsuphatase (14 U/ml) were
purchased from Sigma (Sigma-Aldrich S.r.l., Milan, Italy); S-nitrosoglutathione (GSNO) was purchased
from Cayman Chemical (Cabru s.a.s. Milan, Italy).
Apparatus
LC analyses were carried out on a Hewlett Packard HP 1050 system equipped with a quaternary
pump, an UV/VIS diode array detector, an autosampler and a vacuum degasser. Separations were done
by reverse phase elution (Merck Licrosphere RP8 column; 250  4.6 mm i.d.; particle size 5 Am) in the
conditions previously described by us (Carini et al., 2002).
Chemiluminescence analyses of plasma NOx and S-nitrosothiols were performed with a Sievers
Instruments Model 280 Nitric Oxide Analyzer (NOAk; Sievers, Boulder, CO, USA; Sensor Medics,
Milan, Italy).
Animal treatment
Male Wistar rats (Charles River, Calco, LC, Italy; 220 F 10 g body weight) were maintained in
compliance with the policy on animal care expressed in the National Research Council guidelines
(NRC 1985). The animals were housed individually in stainless steel cages under standard conditions
(temperature 22 F 2 jC; 50 F 10% relative humidity; artificial light from 06:00 to 20:00 h). Food
laboratory chow and drinking water were available ad libitum; animals were fasted overnight before
the drug treatment. NCX 4016 was dissolved in PEG 400 (150 mg/ml) immediately before
administration. In a first set of experiments, rats (n = 5 for each time point) were orally treated (by
gavage) with the drug (100 mg/kg) and sacrificed 0.5, 1, 2, 4, 6, 8, 12, 18, 24 h post-administration. A
second group of animals (n = 5 for each time point) were i.p. treated with 100 mg/kg NCX 4016 and
sacrificed 0.5, 1, 2, 3, 4 h post-administration. Two additional groups of animals (n = 5) were orally or
i.p. treated with an equal volume of drug vehicle (pre-dose controls). Scheme I summarizes the
experimental protocol.
Blood, plasma and tissue preparation
For blood and plasma sampling, the animals were anesthetized with intraperitoneal sodium
pentobarbital (60 mg/kg) and venous blood withdrawn from abdominal vein by heparinized syringes.
Venous blood was collected into tubes containing sodium heparinate (5000 U/ml) and EDTA (final
concentration 30 AM), added with NaF (8 mg per ml) and centrifuged at 1500 g for 10 min at 4 jC. The
plasma samples were then transferred to 2 ml cryovials and stored at  80 jC until the analysis of NOx
(chemiluminescence) and drug and metabolites (HPLC). Plasma aliquots from p.o./i.p. treated animals
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glucuronidase/arylsuphatase.
Blood samples used for measurement of endogenous RS-NO levels were collected into tubes
containing EDTA (final concentration 2 mM) and NEM (final concentration 5 mM). All the samples
were then centrifuged and stored as above described.
For tissue sampling, control and treated rats were killed by cervical dislocation; the hearts were
excised and immediately perfused with cold NaCl (0.9%, w/v), minced in cold KCl (1.15%, w/v) and
homogenized in 0.1 M phosphate buffer, pH 7.4 using an ultra-turrax T25 homogenizer (Janke and
Kunkel, Ika). Heart homogenates (0.1 g wet tissue/ml) were deproteinized with cold ethanol containing
10% perchloric acid (2 vol.), centrifuged at 20,000 rpm (5 min) and the supernatants, filtered through a
0.2 Am filter, submitted to chemiluminescent and HPLC analyses (20 Al aliquots). For chemiluminescent
analysis of NOx, prior to determination the heart homogenate was washed with dichloromethane (3
volumes for 3 times) to eliminate drug and metabolites. The organic phases were discarded and the
aqueous residue deproteinized and treated as above described. In orally treated animals the stomach was
removed, opened and the gastric content recovered and extracted twice with 5 ml acetonitrile. In parallel
the gastric mucosa was thoroughly rinsed with the same solvent. The collected organic phases were
evaporated to dryness under vacuum, taken up in 0.5 ml mobile phase and submitted to HPLC analysis
for drug and metabolites.
Ozone-based chemilumiscent determination of plasma and tissue NOx and RS-NO
NOx levels were determined on 0.25 ml plasma aliquots deproteinized with cold ethanol (1:2 v/v)
and centrifuged at 14,000 rpm (5 min) according to the method of Braman and Hendrix (1989) (VCl3
reduction). The NOx content in plasma and tissues was determined on calibration curves prepared by
adding known amounts of sodium nitrate to blank plasma or tissue homogenates in the concentration
range 0.5-100 AM and expressed as AM and nmoles/g wet tissue respectively. RS-NO were determined
by a copper(I)/iodide/iodine-mediated cleavage of RS-NO to form NO (Marley et al., 2000), which was
quantified by its chemiluminescent reaction in gas phase with ozone. The reaction chamber containingFig. 1. Structures of NCX 4016 and of some postulated metabolic products.
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One minute prior to sample injection (400 Al plasma + 100 Al of a 0.5% sulphanilamide solution in 0.1
M HCl), 200 Al of copper (II) sulphate (200 mM) was added. This solution was constantly purged
with helium and used only once per sample. The RS-NO content in plasma was determined on
calibration curves prepared with GSNO (concentration range 0.05–5.0 AM) and expressed as AM.
Data collection and analysis was performed using the NOAnalysisk software (Sievers, Boulder, CO,
USA).
Statistical analysis
All data are expressed as mean F S.D. (n = 5). For RS-NO and NOx parameters, the significance of
differences among post-administration and pre-dose values was assessed by one way analysis of varianceFig. 2. HPLC analysis of plasma from rats p.o. treated with 100 mg/kg NCX 4016. a) Typical chromatogram of a plasma sample
relative to 6 h post-administration. b) Time-course of SA formation in plasma.
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Statistical analysis was performed by using the Prism software package (GraphPad Software Inc., San
Diego, CA, USA).Results
Plasma levels of drug metabolites, NOx and nitrosothiols
In previous studies (Carini et al., 2002) we have developed and validated a reverse-phase HPLC
method able to efficiently separate NCX 4016 and its postulated metabolites arising from cleavage of
different ester functions (Fig. 1) in biological matrices. The method has been applied in this study forFig. 3. HPLC analysis of plasma from rats i.p. treated with 100 mg/kg NCX 4016. a) Typical chromatogram of a plasma sample
relative to 1 h post-administration. b) Time-course of SA and NCX 4015 formation in plasma.
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4016. Fig. 2a shows a representative chromatographic profile of plasma from orally treated rats (6 h post-
administration). At all the observation times (0.5–24 h), no unchanged drug, nor the postulated
metabolites were ever observed following oral administration and, as previously seen in rats chronically
treated with 30 mg/kg NCX 4016 (Napoli et al., 2002), the only circulating metabolite was salicylic acid
(SA), whose kinetics of formation, with a peak between 6-8 h (87.0 F 8.4 and 82.6 F 7.8 Ag/ml), is
reported in Fig. 2b.
No metabolic species were liberated following enzymatic hydrolysis of plasma samples. This
excludes metabolites circulating in conjugated form.
Conversely, in i.p. treated animals (Fig. 3a reports the chromatogram relative to 1 h post-dose), beside
the main metabolite SA, whose formation is maximal at 1 h (Cmax 127.7 F 6.9 Ag/ml and plateauFig. 4. Time-course of plasma NOx and S-nitrosothiols formation. a) p.o. treatment. NOx values were significant (p < 0.05) vs.
pre-dose values (32.1 F 3.5 AM) in the 1–4 h interval. RS-NO values were significant (p < 0.05) vs. pre-dose values (1.45 F
0.29 AM) in the 1–12 h interval. b) i.p. treatment. All values were significant (p < 0.05) vs. pre-dose values (29.7 F 3.2 AM
for NOx and 1.28 F 0.31 AM for RS-NO).
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ester) which participates to the delivery of the NO moiety, is also detectable at the first observation times,
although at low concentration levels (Cmax 3.83 F 0.41 Ag/ml 1 h post-dose) (Fig. 3b). No further
NCX 4015 was released after enzymatic hydrolysis. The absence of NCX 4015 in orally treated animals
and the very low plasma levels following i.p. administration indicate rapid conversion of this metabolite
or tissue distribution/sequestration.
Then we determined by chemiluminescence analysis the plasma levels of NOx and RS-NO. Oral
treatment (Fig. 4a) induced a time-dependent increase of NOx levels, more than a 7-fold increase at the
6th h compared with the pre-dose values (238.7 F 7.2 vs. 32.1 F 3.5 AM) and a parallel significant rise
in S-nitrosothiols (peak at 4 h, 3.60 F 0.14 vs. 1.45 F 0.29 AM). Following i.p. administration (Fig. 4b)
the increase in both the parameters was earlier and significantly more pronounced: peak at 1 h (577.4 F
18.6 AM for NOx; 16.3 F 2.9 AM for RS-NO) and plateau between 1 and 2 h. The kinetics of plasma RS-
NO formation following p.o. or i.p. treatment strictly parallels those of blood nitrosylhemoglobin,
previously determined by ESR in the rat in the same experimental conditions (p.o. and i.p. administration
of 100 mg/kg NCX 4016), where the maximal formation of the paramagnetic complex was observed at 4-Fig. 5. Chromatographic profiles of myocardial samples from untreated (a) and i.p. treated animals (100 mg/kg; 1 h post-
administration). Insert: UV-DAD spectra of peaks with R.T. 18.36 min (NCX 4015) and R.T. 26.46 min (NCX 4016).
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plasma thiol-containing molecules which readily deliver NO in the presence of transition metals
(Pawloski et al., 2001; Gross, 2001).
Myocardial levels of drug metabolites and NOx
Since it has been recently demonstrated that chronically administered NCX 4016 (5 days; 10, 30 or
100 mg/kg) displays a dose-dependent cardioprotection in rats subjected to myocardial ischemia/
reperfusion injury (reduction of the incidence of ventricular tachycardia and fibrillation and of infarctFig. 6. Distribution of NCX 4016 and metabolites (a) and of NOx (b) in the heart of animals i.p. treated with 100 mg/kg. NOx
values were significantly different (p < 0.05) from the pre-dose values (147.5 F 9.7 nmoles/g tissue) in the 0.5–2 h interval.
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of the drug and metabolites and of NOx.
This was done to explore whether the effect could be ascribed to a specific compartmentalization of
the drug/metabolites within the heart. No unchanged drug and metabolites were detectable at any
observation time following a single oral dose, and NOx levels were always in the range of the controls
(177.5 F 9.7 nmoles/g tissue; data not shown). Fig. 5b reports the LC-UV-DAD profile of a myocardial
extract relative to 1 h post-dose after i.p. administration of NCX 4016, where besides SA (R.T. 15.6
min), two sharp peaks (absent in the controls) can be detected (R.T. 18.36 and 26.46 min). Both the
compounds were identified, on the basis of their typical UV fingerprints (insert of Fig. 5b) as NCX 4015
and unchanged drug respectively. Thus, the analysis of myocardial samples at different post-adminis-
tration times (Fig. 6a) indicates that, unlike to that observed following p.o. treatment, there is a rapid
compartmentalization within the heart of the unchanged drug, which rapidly disappears (Cmax at 0.5 h =
22.6 F 2.4 Ag/g tissue) in favour of its breakdown products (Cmax SA 68.4 F 2.9 Ag/g tissue at 2 h;
Cmax NCX 4015 33.5 F 3.2 Ag/g tissue).Fig. 7. HPLC analysis of gastric content from rats p.o. treated with 100 mg/kg NCX 4016. a) Chromatographic profile of a
sample relative to 6 h post-administration. b) Time-dependent decline of gastric NCX 4016 and formation of NCX 4023 (de-
acetylated metabolite). c) Correlation between plasma levels of SA and residual gastric levels of NCX 4016 + NCX 4023.
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147.5 F 9.7 nmoles/g tissue (pre-dose value) to 210.4 F 14.1 nmoles/g tissue (p < 0.05) at 1 h post-
dose and to 190.8 F 9.3 nmoles/g tissue at the 2 h time point, followed by a decline to 138.7 F 12.0
nmoles/g tissue at the last observation time.
Analysis of gastric content
To check the stability of NCX 4016 in the acidic gastric milieu, to explain the different behaviour/
distribution of the drug following p.o. or i.p. administration and for a better understanding of the role of
the gastrointestinal tract in the absorption of the drug, we have examined the gastric content of the orally
treated animals at different post-dosing times by HPLC. The unchanged drug (high levels) and its de-
acetylated metabolite NCX 4023 (low levels) were detected at all the observation times, but no one of
the other postulated metabolites (Fig. 7a reports the chromatogram of the extract relative to 6 h post-
administration). This, and especially the absence of de-nitrated metabolites NCX 4017 and NCX 4019,
indicates a high stability of the drug and of the nitrate ester function in the gastric environment, and
indirectly excludes a local release of NO. The time-dependent decline of NCX 4016 and formation of
NCX 4023 in the gastric content (both quantitated by HPLC analysis) is reported in Fig. 7b: the results
indicate a slow absorption process of the drug, since 2 h post-administration, the residual gastric amount
(calculated as sum of the unchanged drug and its de-acetylated metabolite) accounts for more than 80%
of the administered dose, and high levels of NCX 4016 are still detectable at the 8th h post-dose
(approximately 30% of the dose). The kinetics of NCX 4016 disappearance from the stomach is
inversely related to that of plasma formation of the main metabolite SA: the slow release of NCX 4016
from the stomach is confirmed by the highly significant negative correlation between residual gastric
amounts of the drug and plasma salicylate levels (Fig. 7c, r2 = 0.9549; p= 0.0008).Discussion
The results of this study provide clear evidence that NCX 4016 is able to slowly, but progressively
release the vasodilating moiety, NO, after oral administration in the rat. Some of this NO is metabolically
converted to the oxidation products, NO2
- and NO3
-. Another proportion of the NO is stored as
nitrosylhemoglobin HbFe(II)NO and S-nitrosothiols. The perfect match, for the entire time period (1-
24 h), between the plasma peak of salicylic acid and that of the final oxidized metabolites of NO (NOx)
suggests a slow absorption/distribution process of the molecule, with a peak of NO delivery between 4
and 6 h. The results relative to i.p. administration (100 mg/kg) show a more pronounced and rapid NO
delivery, still coincident with the plasma peak of SA, and small but well detectable NCX 4015 levels.
One of the findings of major relevance of our work is the demonstration that after acute i.p.
administration, NCX 4016 and its active metabolite NCX 4015 are able to reach the heart. Concomitant
to their presence, we observe in myocardial tissue an increase of the NOx levels, which, although
considered indirect marker for NO, are a clear indication of its formation. Very likely, due to the high
concentration of NCX 4016 following i.p. administration, part of this is able to escape to the hematic/
hepatic hydrolytic breakdown and localize within the myocardial tissue, the drug intake being favoured
by its lipophilic character (log P = 2.89), reflecting the passage through the sarcolemma (Horowitz and
Powell, 1986).
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NOx levels in this tissue following administration of a NO-donor drug. In our case the increase in NO
levels in the heart is further corroborated by the previous experiments where, using the more specific and
unequivocal technique, ESR, we have observed a clear cut increase in the signal relative to the
nitrosylmyoglobin paramagnetic complex (Carini et al., 2001) after i.p. treatment of rats with the same
dosage of drug.
The strictly parallel relationship between concentrations of unchanged drug, the NCX 4015
metabolite and increases in NOx could indicate that the delivery of NO to myocardial tissue, after
i.p. administration, is mediated, in addition to bioactive storage forms of NO, by nitrate ester species
which may undergo a denitration process in situ.
After p.o. treatment the levels of unchanged drug and metabolites in myocardial tissue are below the
limit of detection, and NOx levels were not statistically different from the pre-dose values. This means
that cardioprotection (Rossoni et al., 2001) with chronically administered NCX 4016 is predominantly
mediated by an increase of circulating bioactive storage forms (nitrosylhemoglobin and plasma RS-NO),
which have been shown to triplicate after oral chronic treatment (Napoli et al., 2002).
The second major finding is the demonstration (although indirect) that no de-nitration occurs in the
upper gastrointestinal tract following oral administration. The experiments performed on the release of
NCX 4016 from the stomach are evidence that the drug is stable in the gastric acidic milieu (no de-
nitrated metabolites and small amounts of the O-deacetylated derivative NCX 4023 were detected up to
8 hours post-dosage), where it persists basically in unchanged form until 12 h, with a slow and
progressive decline which strictly parallels the appearance in plasma of salicylic acid. The same
behaviour was observed in previous and preliminary studies on gastric content from rats treated with a
single lower oral dose (50 mg/kg) (Carini et al., 2000). These results are in contrast with those of
Takeuchi et al. (1998) which found significantly elevated NOx levels in gastric juice after intragastric
administration of NCX 4016 (33 mg/kg) in pylorus-ligated rats. However, since the Authors are dealing
with non-physiological conditions (they do not specify to which extent pylorus ligation might affectScheme II. Postulated metabolic disposition of NCX 4016 following oral and i.p. administration.
M. Carini et al. / Life Sciences 74 (2004) 3291–33053304local gastric pH), and they used for NOx determination the Griess method, universally considered as
poorly reliable, we are considering this increase as artifactual or not physiological. Further studies are in
progress to estimate the gastric levels of NOx and RS-NO following oral administration by the more
sensitive, specific and unequivocal chemiluminescent assay.
Hence, we hypothesize that the drug reaches the intestine in the unchanged form, and the part that
escapes the attack of the hydrolytic enzymes of intestinal microflora (extra-hepatic metabolism) is
absorbed as such, enters the liver where, as previously demonstrated (Carini et al., 2002), it undergoes
rapid conversion to SA and NCX 4015. Scheme II summarizes the metabolic disposition of the drug.Conclusions
In conclusion, the results of this study demonstrate that the NO-dependent gastroprotective effect of
NCX 4016 is not due to a luminal NO release and subsequent diffusion through the gastric mucosa, but
to a systemic metabolism of NCX 4016 and consequent NO release which, through the bioactive storage
forms, is delivered at gastric level. The slow release process from the stomach followed by an extensive
hepatic first pass is further confirmed by the fact that in plasma we have never found the unchanged
drug, nor its O-deacetylated metabolite (NCX 4023), NCX 4015 or its de-nitrated product HBA, nor
HBAC. The key role of gastrointestinal tract in drug absorption and NO delivery is further substantiated
by our previous studies (Carini et al., 2001) where significantly different peak levels of nitrosylhemo-
globin (the unequivocal blood marker of NO release) were determined after p.o. and i.p. administration
of 100 mg/kg NCX 4016 in the rat (0.68 F 0.14 AM vs. 5.5 F 1.2 AM). All these data explain why oral
administered NCX 4016 does not give rise, in vivo, to the typical adverse effects of conventional NO-
donors since the stomach acts as a reservoir for the drug, causing it to release NO slowly.Acknowledgements
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